Thymuskin® Continued...

Thymuskin® was originally developed to prevent hair loss in patients undergoing chemotherapy and/or radiation treatment.  In the early 1980's a Germany company named Vita-Cos-Med Klett-Loch GmbH developed a topical formulation that they believed would be highly effective in preventing hair loss during anti-cancer treatments.  Several teams of oncologist, dermatologist, and medical physicians practicing at university hospitals of Hiedelberg, Darmstadt, Munster and Hanover decided to perform clinical trials using this solution.

After great success, more trials were conducted in other areas of hair loss with Thymuskin® as its main component. Below is a list of documented studies performed during this time.  The research and studies were carried out in close cooperation with leading  German dermatological hospitals and medical universities.

1. Alopecia during treatment with different chemo-therapeutical regimen: Prof. Dr. Claus O Kohler

2. Summary of the adjuvant local application of Thymuskin preparation in patients during cytostatic chemotherapy: Prof. Dr. N-P Lupke

3. Prelimiary report Thymuskin trial oncology: Prof. D. H. Denck, Dr. med G.M. Wallner

4. Final report Thymuskin trial oncology: Prof. Dr. H. Denck, Dr. med G.W. Wallner

5.  Report on the clinical efficacy of Thymuskin for the treatment of various types of alopecia:  Prof. Dr. med M. Hagedorn

6. Thymuskin: New therapeutical approach in treatment of alopecia androgenetica and alopecia areata:  Dr. med K Mossler

7. Local therapy with thymus extracts in patients with alopecia areata totalis sive universalis: Prof. Dr. med M. Hagedorn, Dr. med K. Mossler

8. Female alopecia-diagnostic and therapeutical approach: Prof. Dr. T. Rabe, Prof. Dr. B. Runnebaum

9. And to list our most recent clinical trial conducted in Italy by the International Italian Society of Plastic-Aesthetic and Oncologic Dermatology in October 2008 titled:  Clinical Investigation on the effect of a topical lotion and shampoo containing synthetic thymus peptides on androgenetic alopecia and chronic telogen effluvium in women.  

Results in this trial concludes that- low molecular weight peptides obtained synthetically in a lab (GKL02) have shown that they have an effect on some common hair complaints, expecially in reducing hair loss and some accompanying symptoms, such as redness, dandruff, pruritus and seborrhea. Due to these qualities their support can be used in the initial phases of androgentic thinning and to contain chronic telogen effluvium. 

The mean molecular weight of these individual peptides vary between 180 and 600 daltons which aid trans follicular penetration while the amino acid composition has been useful for the following reasons.

• as a pool for the synthesis of keratins

• in the stimulation of keratinocyte growth

• in the participation of immunologic homeostasis of the skin